1. Home
  2. CDT vs STRR Comparison

CDT vs STRR Comparison

Compare CDT & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • STRR
  • Stock Information
  • Founded
  • CDT 2019
  • STRR 1985
  • Country
  • CDT United States
  • STRR United States
  • Employees
  • CDT N/A
  • STRR N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • CDT Health Care
  • STRR Health Care
  • Exchange
  • CDT Nasdaq
  • STRR Nasdaq
  • Market Cap
  • CDT 11.9M
  • STRR 13.3M
  • IPO Year
  • CDT N/A
  • STRR N/A
  • Fundamental
  • Price
  • CDT $0.11
  • STRR $4.02
  • Analyst Decision
  • CDT
  • STRR
  • Analyst Count
  • CDT 0
  • STRR 0
  • Target Price
  • CDT N/A
  • STRR N/A
  • AVG Volume (30 Days)
  • CDT 24.0M
  • STRR 8.2K
  • Earning Date
  • CDT 11-18-2024
  • STRR 11-06-2024
  • Dividend Yield
  • CDT N/A
  • STRR N/A
  • EPS Growth
  • CDT N/A
  • STRR N/A
  • EPS
  • CDT N/A
  • STRR N/A
  • Revenue
  • CDT N/A
  • STRR $47,147,000.00
  • Revenue This Year
  • CDT N/A
  • STRR $19.97
  • Revenue Next Year
  • CDT N/A
  • STRR $41.50
  • P/E Ratio
  • CDT N/A
  • STRR N/A
  • Revenue Growth
  • CDT N/A
  • STRR N/A
  • 52 Week Low
  • CDT $0.10
  • STRR $3.43
  • 52 Week High
  • CDT $7.83
  • STRR $6.55
  • Technical
  • Relative Strength Index (RSI)
  • CDT 41.52
  • STRR 48.07
  • Support Level
  • CDT $0.10
  • STRR $3.88
  • Resistance Level
  • CDT $0.14
  • STRR $4.09
  • Average True Range (ATR)
  • CDT 0.01
  • STRR 0.18
  • MACD
  • CDT 0.00
  • STRR -0.00
  • Stochastic Oscillator
  • CDT 18.06
  • STRR 38.51

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About STRR Star Equity Holdings Inc.

Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.

Share on Social Networks: